The Dow dropped more than 650 points and the S&P 500 slid nearly half a percent on Tuesday as renewed violence in the Middle East sent oil prices surging — but scroll past the red headline numbers and today’s list of top gaining stocks today reveals a market humming with company-specific excitement. Two biotech names scored genuine clinical trial wins, the quantum computing sector had one of its best days of the year after the U.S. government took equity stakes in two players, and a wave of AI-infrastructure deal announcements from Qualcomm and Corning lifted names across the semiconductor and materials space. Here are the 10 stocks that mattered most today.

Tuesday’s Session at a Glance:

Despite the broad market weakness — driven largely by reports that Yemen’s Houthi rebels struck four Saudi cities with drones and missiles, wounding more than 70 people — several distinct pockets of the market had a genuinely excellent day.

1. Roivant Sciences (ROIV) | Closed $41.48, Up ~19%

A Lung Disease Drug Delivers a Statistically Significant Knockout

Roivant Sciences shares surged almost 19% after its pulmonary hypertension candidate mosliciguat met the primary endpoint in a mid-stage clinical trial, closing at $41.48, up $6.55 from the prior session.

Full Data Snapshot:

Why It Gained:

Roivant’s subsidiary Pulmovant reported that its inhaled drug mosliciguat achieved a statistically significant 56% reduction in pulmonary vascular resistance over 16 weeks compared to placebo in patients with pulmonary hypertension associated with interstitial lung disease — a first-in-class mechanism as a soluble guanylate cyclase activator. The company also disclosed it recently received FDA approval for Lisraya (brepocitinib) in a separate indication.

Bull Case: A $3.9 billion cash position, an actively growing commercial portfolio (Lisraya, plus royalty settlements from Moderna, Pfizer, and BioNTech litigation), and now a positive mid-stage readout in a genuinely differentiated drug class all support continued re-rating.

Bear Case: This remains a Phase 2 result, not a pivotal trial — full statistical detail on hazard ratios and long-term safety will need to hold up in a larger Phase 3 program before mosliciguat becomes a commercial reality.

Technicals: Today’s gain was among the largest single-day moves for ROIV in the past year, pushing shares well above recent trading ranges on heavy volume.

Forecast: With multiple pipeline readouts still due in the second half of 2026 (including IMVT-1402 data in cutaneous lupus), Roivant has several more binary catalysts ahead that could extend today’s momentum.

Why This Matters: Roivant’s diversified multi-subsidiary model — spreading risk across several drug candidates and an active litigation-settlement business — is now visibly paying off, with today’s win adding to a string of positive catalysts this year.

2. Pharvaris (PHVS) | Up 14%

A Rare Disease Drug Clears Its Final Major Hurdle

Pharvaris shares jumped more than 14% after its lead candidate, deucrictibant XR, met the primary endpoint and all secondary endpoints in the pivotal Phase 3 CHAPTER-3 study for preventing hereditary angioedema (HAE) attacks.

Full Data Snapshot:

Why It Gained:

The CHAPTER-3 study is the first and only prophylaxis Phase 3 trial to cover all three types of hereditary angioedema, and every single secondary efficacy endpoint achieved statistical significance alongside a well-tolerated safety profile — a clean sweep that removes one of the last major clinical risks facing the company’s core franchise.

Bull Case: With both an on-demand treatment (already filed as an NDA) and now a prophylaxis therapy with pivotal Phase 3 success, Pharvaris is positioned to offer a complete end-to-end portfolio for bradykinin-mediated angioedema — a genuinely differentiated commercial story in a market currently dominated by injectable therapies.

Bear Case: Marketing authorization applications aren’t planned until 1H 2027, meaning meaningful revenue is still well over a year away, and the company remains pre-commercial with ongoing cash burn despite its extended runway.

Technicals: Today’s double-digit move on heavy volume reflects genuine institutional re-rating rather than short-term speculative trading, given the binary, data-driven nature of the catalyst.

Forecast: With both core clinical risks now cleared (on-demand NDA filed, prophylaxis Phase 3 successful), the next major catalysts shift toward regulatory review timelines and eventual commercial launch readiness.

Why This Matters: Pharvaris’ clean Phase 3 sweep is a reminder that genuine, statistically unambiguous trial wins in rare disease can still move a stock double digits even on a day when the broader market is deeply in the red.

3. Solaris Energy Infrastructure (SEI) | Closed $63.62, Up 15.66%

A Power Infrastructure Stock Rides the AI Electricity Boom

Solaris Energy Infrastructure shares jumped nearly 16% to $63.62 after the modular power-generation company sharply raised its adjusted EBITDA guidance for both the third and fourth quarters of 2026.

Full Data Snapshot:

Why It Gained:

Solaris cited stronger contributions from its core power services operations and better-than-expected performance from recently acquired businesses — including the July 2026 acquisition of Global Energy Services Alliance and the earlier purchase of Omega Foundation Services — as driving the dramatic guidance raise, with expanded long-term contracts adding more than $100 million of incremental annual EBITDA.

Bull Case: Solaris plans to grow generation capacity toward roughly 3,200 megawatts by the end of 2029, directly riding the same data-center and AI electricity demand wave lifting names like Bloom Energy, and the scale of today’s guidance raise (up to 48% at the midpoint for Q4) suggests genuine, not incremental, momentum.

Bear Case: With roughly $1 billion in remaining 2026 capital expenditures planned, Solaris carries meaningful execution and financing risk as it scales toward its 2029 capacity target, and the stock’s wide 52-week range ($24.57–$86.19) reflects a name still finding its valuation footing.

Technicals: Today’s move on volume of 1.87 million shares against a 2.87 million average reflects strong but not extreme conviction buying, with shares still well below their 52-week high of $86.19.

Forecast: With two consecutive quarters of guidance raises now on the books and long-term contracts already locking in incremental EBITDA, Solaris looks positioned to continue benefiting from the broader AI-driven power demand theme through the rest of 2026.

Why This Matters: Solaris’ guidance raise is further evidence that the AI power-demand story extends well beyond the household names (Bloom Energy, nuclear plays) into specialized modular power infrastructure providers most investors have never heard of.

4. IonQ (IONQ) | Up ~12%

A Quantum Computing Company Nearly Doubles Its Revenue Guidance Overnight

IonQ shares surged as much as 12% after the quantum computing company raised its full-year 2026 revenue guidance to $450 million–$460 million — up dramatically from a standalone prior guide of $280 million–$290 million — following the close of its acquisition of SkyWater Technology.

Full Data Snapshot:

Why It Gained:

IonQ held its first joint Investor Day following the SkyWater acquisition, unveiling its sixth-generation Superion quantum computing platform manufactured at SkyWater’s own semiconductor foundry, while also announcing an $8.18 million quantum-security deal with Congruity360 — one of the largest commercial quantum-security agreements in the U.S. to date. Management noted Q2 revenue of $80 million was nearly twice the combined revenue of every other publicly traded quantum computing company.

Bull Case: The SkyWater acquisition gives IonQ actual U.S.-based semiconductor manufacturing capacity — a genuine structural advantage over quantum peers that remain purely R&D-stage — and a backlog of $485 million in remaining performance obligations signals real customer commitments, not speculative revenue.

Bear Case: Some analysts remain skeptical of quantum computing valuations broadly given the technology’s early commercial stage, and combining two companies’ financials always carries integration risk, particularly around the elimination of prior intercompany revenue arrangements.

Technicals: Today’s gain extends a powerful 2026 run for IonQ, with the stock among the best performers in the broader quantum computing basket alongside Rigetti and D-Wave.

Forecast: With Superion now in production at SkyWater’s foundry and a nearly-doubled revenue base, IonQ’s next test will be proving the combined entity can convert its expanded backlog into consistent quarterly execution.

Why This Matters: IonQ’s transformation from a pure-play quantum research company into a company with actual chip manufacturing capacity marks a meaningful maturation point for the entire quantum computing sector.

5. Rigetti Computing (RGTI) | Closed $16.06, Up 5.66%

The U.S. Government Just Became a Quantum Computing Shareholder

Rigetti Computing shares rose as much as 12.2% intraday, closing up 5.66% at $16.06, after signing a definitive $100 million agreement with the U.S. Department of Commerce to accelerate superconducting quantum computing research — with the government taking an equity stake as part of the deal.

Full Data Snapshot:

Why It Gained:

The funding will support three specific R&D projects: miniaturized readout electronics, expanded cryogenic capacity via a new cryostat architecture, and fabrication capabilities for high-connectivity chip designs — with the Department of Commerce receiving a minority, non-controlling equity stake as a condition of the award, mirroring similar government stakes previously taken in Intel and GlobalFoundries.

Bull Case: A $100 million non-dilutive-in-spirit (though share-based) government commitment validates Rigetti’s technical roadmap and provides substantial capital runway, while the government’s own financial stake in the stock creates an unusual alignment of incentives favoring continued federal support.

Bear Case: The issuance of roughly 7.74 million new shares to the Commerce Department represents real dilution for existing shareholders, and despite today’s pop, RGTI remains down roughly 26% year-to-date, reflecting a still-skeptical broader market view of quantum computing commercialization timelines.

Technicals: Shares gave back roughly half of their intraday high-water gain by the close, suggesting some profit-taking after the initial premarket enthusiasm faded.

Forecast: With peer D-Wave Quantum receiving matching terms in a parallel deal, the quantum sector now has explicit U.S. government backing — a structural tailwind that could support valuations even as commercialization timelines remain years out.

Why This Matters: The government taking direct equity stakes in quantum computing companies — following a similar playbook used with legacy chipmakers — signals quantum computing has now been formally classified as strategic national infrastructure.

6. Qualcomm (QCOM) | Up 9.5%

A $60 Billion Amazon Partnership Reignites the AI Chip Story

Qualcomm shares spiked as much as 9.5% after announcing a multi-generational collaboration with Amazon to build customized AI silicon and ultra-fast optical connectivity solutions, with the deal potentially tied to up to $60 billion in future payments to Qualcomm.

Full Data Snapshot:

Why It Gained:

The partnership centers on building energy-efficient custom silicon for AWS’s large-scale AI data centers, with vesting of Amazon’s warrant tied to binding purchase orders and actual product purchases — meaning Amazon’s financial upside is directly linked to how much AI chip business it actually gives Qualcomm, a strong signal of genuine commercial intent rather than a symbolic partnership announcement.

Bull Case: A deal potentially worth up to $60 billion over its lifetime would be transformative for Qualcomm’s data-center ambitions, diversifying the company well beyond its traditional smartphone chip business into the fastest-growing segment of the semiconductor market.

Bear Case: The warrant structure means Amazon’s equity stake grows precisely as Qualcomm becomes more dependent on Amazon as a customer — a single-customer concentration risk that could pressure Qualcomm’s negotiating leverage in future contract cycles.

Technicals: Today’s move puts Qualcomm back into positive territory for 2026 after the stock had been lagging the broader semiconductor sector heading into the announcement.

Forecast: The pace at which Amazon’s warrant shares vest — tied directly to real purchase orders — will be the clearest forward indicator of how quickly this partnership translates into actual Qualcomm revenue.

Why This Matters: Qualcomm joining the AI custom-silicon race alongside Broadcom and Marvell signals the market for AI-specific chips is broadening beyond Nvidia’s dominant position faster than many investors expected.

7. Corning (GLW) | Up 8%

Fiber Optic Glass Becomes AI Infrastructure’s Hottest Commodity

Corning shares jumped as much as 8% to $166.75 after Verizon announced a multi-year, multi-billion-dollar supply agreement for over 80 million miles of high-density optical fiber running from 2027 through 2032.

Full Data Snapshot:

Why It Gained: The deal supports Verizon’s push toward 40–50 million broadband passings while explicitly serving as backbone infrastructure for AI hyperscaler workloads — the second major multi-billion-dollar fiber commitment Corning has landed in 2026, following a similar agreement with Amazon in June and Nvidia’s direct investment in Corning’s U.S. manufacturing capacity in May.

Bull Case: Landing back-to-back mega-deals with Nvidia, Amazon, and now Verizon in a single year demonstrates Corning has become genuinely indispensable physical infrastructure for the AI buildout, not just a beneficiary of secondary demand.

Bear Case: At roughly 90% YTD gains already priced in, expectations for continued deal flow are now extremely high, and any slowdown in hyperscaler capex could hit sentiment hard given how much of Corning’s re-rating rests on the AI infrastructure narrative specifically.

Technicals: Today’s gain builds directly on Corning’s already-strong 2026 technical uptrend, with the stock making fresh highs on the news.

Forecast: With long-term customer commitments now locked in through 2032, Corning’s growth visibility has improved materially — the next catalyst watch is whether the company can convert this demand into further U.S. manufacturing capacity expansion announcements.

Why This Matters: Corning’s rally today, alongside gains at Intel (+9%), AMD (+6%), and HPE (+8%) on the same news cycle, shows how a single infrastructure deal can lift an entire cohort of AI-adjacent industrial names simultaneously.

8. Bloom Energy (BE) | Up 8%

Index Inclusion Delivers an Instant, Mechanical Rally

Bloom Energy shares jumped 8% after being added to the S&P 500 index, effective before the open of trading on Monday, September 21, alongside Palantir Technologies and Illumina, which will replace Molson Coors, Builders FirstSource, and Trade Desk in the index.

Full Data Snapshot:

Why It Gained: S&P 500 index inclusion is a mechanical catalyst — index funds and ETFs tracking the S&P 500 are required to buy shares of newly added companies, creating genuine forced buying pressure independent of any change in the underlying business fundamentals, and the two-week lead time before the effective date often produces exactly this kind of pre-positioning rally.

Bull Case: Beyond the mechanical inclusion trade, Bloom’s underlying business — providing on-site fuel cell power for AI data centers — continues to benefit from the same electricity-demand supercycle lifting Solaris Energy and other power infrastructure names today.

Bear Case: Index-inclusion rallies can partially or fully reverse once the actual effective date passes and the forced-buying flow is complete, meaning some of today’s gain may prove temporary rather than fundamentally driven.

Technicals: Today’s gain adds to an already powerful 2026 uptrend for Bloom Energy, which has been one of the year’s best-performing large-cap industrial names.

Forecast: Watch for potential profit-taking around the September 21 effective date once index funds complete their required buying, a pattern common to many past S&P 500 inclusion events.

Why This Matters: Bloom’s addition to the S&P 500 — alongside fellow high-growth names Palantir and Illumina — is itself a signal of how mainstream the AI-power-infrastructure trade has become, graduating from a niche thematic bet to a core S&P 500 holding.

9. D-Wave Quantum (QBTS) | Up ~5%

Rigetti’s Quantum Rival Gets the Same Government Backing

D-Wave Quantum shares climbed roughly 5% to $17.46 after securing matching terms in the same U.S. Department of Commerce CHIPS Act funding round that lifted Rigetti Computing today, with the government taking equity stakes in both companies simultaneously.

Full Data Snapshot:

Why It Gained: The U.S. Commerce Department finalized CHIPS Act funding awards for both Rigetti and D-Wave on the same day, taking minority, non-controlling equity stakes in each company — a coordinated government initiative treating superconducting and other quantum computing architectures as strategic national technology, similar to prior interventions in the legacy semiconductor industry.

Bull Case: Simultaneous government backing for multiple quantum architectures (Rigetti’s superconducting approach, D-Wave’s quantum annealing approach) suggests Washington is hedging its bets across quantum computing technologies broadly, providing a durable policy tailwind for the whole sector rather than picking a single winner.

Bear Case: D-Wave remains down roughly a third year-to-date even after today’s gain, and government equity stakes introduce the same dilution dynamic facing Rigetti — a real cost that doesn’t disappear just because the headline funding number looks attractive.

Technicals: Today’s gain, while smaller than Rigetti’s peak intraday move, still represents a meaningful bounce for a stock that has underperformed badly in 2026.

Forecast: With government backing now established, D-Wave’s next catalysts will likely center on demonstrating commercial contract wins that validate its distinct quantum annealing approach against competing architectures.

Why This Matters: Today’s coordinated government funding for two competing quantum computing approaches marks one of the clearest policy signals yet that quantum computing has crossed the threshold from speculative research bet to strategic national priority.

10. Coherent Corp (COHR) | Closed $301.88, Up 7%

AI Photonics Rides the Same Wave Lifting Corning and Qualcomm

Coherent shares climbed just over 7% to close at $301.88, up $20.02, as the broader rally in AI infrastructure and photonics names lifted the laser and optical-transceiver maker alongside sector peers Corning and Qualcomm.

Full Data Snapshot:

Why It Gained:

Coherent’s move today came as part of broader sector-wide strength in AI photonics stocks following the Corning-Verizon and Qualcomm-Amazon deal announcements, with Coherent’s own Datacenter and Communications segment — now 79% of total sales and growing 59% year-over-year — directly benefiting from the same optical-connectivity buildout theme driving today’s other AI infrastructure gainers.

Bull Case: Seven consecutive quarters of record revenue, a recent $2 billion strategic investment and purchase commitment from Nvidia, and an average analyst price target implying substantial upside all support continued momentum in Coherent’s core AI datacenter photonics business.

Bear Case: The stock trades at roughly 100x trailing earnings, and shares are still down more than 25% over the past 30 days despite today’s bounce — reflecting genuine investor uncertainty about how much further this valuation can stretch even with strong underlying fundamentals.

Technicals: Today’s gain is a partial recovery within a stock that has seen 51 moves greater than 5% over the past year, underscoring just how volatile this high-multiple AI infrastructure name remains.

Forecast: With Coherent set to showcase new AI datacenter optics technology at the ECOC 2026 conference later this month, additional product announcements could provide the next catalyst for shares to test back toward analyst price targets.

Why This Matters: Coherent’s participation in today’s rally alongside Corning and Qualcomm shows how a single day’s worth of AI infrastructure deal news can lift an entire ecosystem of photonics and optical-connectivity suppliers simultaneously.

Sector Sentiment Snapshot & Forecast

Today’s gainers cluster into three distinct themes that together tell a story about where genuine excitement is building beneath a red headline tape. Biotech delivered two clean, statistically unambiguous trial wins (Roivant and Pharvaris), a reminder that binary clinical catalysts can move stocks double digits regardless of broader market direction. Quantum computing had one of its best days of the year after the U.S. government took direct equity stakes in both Rigetti and D-Wave, while sector leader IonQ nearly doubled its revenue guidance — collectively signaling that quantum computing has crossed from speculative research bet into recognized strategic infrastructure. And AI physical infrastructure names (Qualcomm, Corning, Coherent, and to a lesser extent Bloom Energy and Solaris) all rallied on genuine new deal announcements rather than sentiment alone, showing the AI buildout narrative continuing to broaden into custom silicon, fiber optics, and power infrastructure well beyond the usual chip giants.

With healthcare broadly weak today on Novartis’s failed drug trials and geopolitical risk in the Middle East keeping oil elevated, the forecast for the rest of the week likely depends on whether today’s company-specific optimism can offset continued macro pressure — a dynamic that could keep volatility elevated heading into Friday’s holiday-shortened trading week.

At a Glance: Today’s Top 10 Gaining Stocks

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and clinical-stage biotech and early-stage quantum computing stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Some prices in this article are approximate or based on premarket/intraday figures where exact closing data was not available at the time of writing. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts